Acrivon Therapeutics, Inc.
Targeted cancer therapies based on precision oncology approaches
- Sector
- Biotech
- Headquarters
- Watertown, MA
- Founded
- 2018
- Latest Form D
- $100M, Nov 2021
- Total capital
- $115M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $115M
- 2 Form D · last Nov 2021
- 59 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 20 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$100M
- Private capital raisedForm D · SEC · 1st filing$15.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Peter Blume-JensenResearcherExecutive Officer, DirectorLinked by 1 patent
- Derek DiRoccoDirectorNamed in SEC Form D filings
- Eric DevroeExecutive OfficerNamed in SEC Form D filings
- Erick GamelinExecutive OfficerNamed in SEC Form D filings
- Kristina MassonExecutive Officer, DirectorNamed in SEC Form D filings
- Marcin CzernikDirectorNamed in SEC Form D filings
Show all 7 people
- Sharon ShachamDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 21- PendingPyrimidine Carboxamide CompoundsUSPTOApplication 19143735
- PendingPhenyl-pyrazole Carboxamide CompoundsUSPTOApplication 19142148
- PendingMethods And Systems For Treating Disease Using An ATR/CHK1 Signaling Pathway InhibitorUSPTOApplication 19351044
Show all 21 patent records
- Pyrimidine Carboxamide CompoundsJul 23, 2026 · Application 19143735Pending
- Phenyl-pyrazole Carboxamide CompoundsJul 23, 2026 · Application 19142148Pending
- Methods And Systems For Treating Disease Using An ATR/CHK1 Signaling Pathway InhibitorJun 18, 2026 · Application 19351044Pending
- Methods And Systems For Treating Disease Using An ATR/CHK1 Signaling Pathway InhibitorJan 8, 2026 · Application 18993467Pending
- Methods And Systems For Treating Disease Using An ATR/CHK1 Signaling Pathway InhibitorOct 7, 2025 · US 12,433,888Granted
- Methods And Systems For Treating Disease Using An ATR/CHEK1 Signaling Pathway InhibitorApplication 63620495Pending
- Pyrimidine Carboxamide CompoundsApplication PCTUS2023086278Pending
- Phenyl-pyrazole Carboxamide CompoundsApplication PCTUS2023085642Pending
- Pyrazolo-pyrimidinone CompoundsApplication 63608086Pending
- Methods And Systems For Treating Disease Using An ATR/CHK1 Signaling Pathway InhibitorApplication PCTUS2023027579Pending
- Pyrazolo-pyrimidinone CompoundsApplication 63472105Pending
- Pyrimidine Carboxamide CompoundsApplication 63436218Pending
- Phenyl-pyrazole Carboxamide CompoundsApplication 63435042Pending
- Methods And Systems For Treating Disease Using An ATR/CHK1 Signaling Pathway InhibitorApplication 63388914Pending
- Indazolo-amino-pyrimidinone CompoundsApplication 19603807Pending
- Pyrazolo-pyrimidinone Compounds For Use In Methods Of Inhibiting WEE1 A KinaseApplication 19491155Pending
- Methods And Systems For Treating Disease Using An ATR/CHEK1 Signaling Pathway InhibitorApplication 19603710Pending
- Indazolo-amino-pyrimidinone CompoundsApplication PCTUS2025012443Pending
- Methods And Systems For Treating Disease Using An ATR/CHEK1 Signaling Pathway InhibitorApplication PCTUS2025011193Pending
- Pyrazolo-pyrimidinone CompoundsApplication PCTUS2024033065Pending
- Indazolo-amino-pyrimidinone CompoundsApplication 63623648Pending
Related companies, and why
- NEONC TECHNOLOGIES HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
- Aeovian PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- ILiAD BiotechnologiesSimilar federal contract value in Biotech · null in contracts
- Circle Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- BigHat Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Entact Bio, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .